UBSはTevaの価格を下げたが,Tevaの収益の予想として"Buy"の評価を維持している. UBS lowered Teva's price target but maintains a "buy" rating as Teva beats earnings expectations.

UBSグループは,テバ製薬産業の目標価格を23ドルに下げたが,買い値を維持した. UBS Group lowered its price target for Teva Pharmaceutical Industries to $23.00 but maintained a "buy" rating. Teva の収益は1株当たり0.52ドルで、その収益はわずか3.89億ドルで予想より下回る。 Teva's earnings per share beat expectations at $0.52, while its revenue was slightly below forecasts at $3.89 billion. 会社の市場キャップは190億円で,債務対利益比は259ドルである. The company's market cap is $19.22 billion, and it has a debt-to-equity ratio of 2.59. 目標が減少しても,アナリストは,株式の総額の"上等"の評価を継続している. Despite the reduced target, analysts still hold an overall "buy" rating on the stock.